Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FIVE PAGES.
|NAME: Campbell, Patrick Kent|
|eRA COMMONS USER NAME (credential, e.g., agency login): P-CAMPBELL|
|POSITION TITLE: Assistant Member, Department of Oncology|
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)
|INSTITUTION AND LOCATION||DEGREE
|FIELD OF STUDY|
|Emory University||PHD||05/2001||Genetics and Molecular Medicine|
|Emory University School of Medicine||Resident||06/2005||Pediatrics|
|St. Jude Children’s Research Hospital||Fellow||06/2008||Pediatric Hematology-Oncology
A. Personal Statement
My work at St. Jude Children’s Research Hospital focuses primarily on patient care and clinical informatics. My clinical focus is on histiocytic disorders including Langerhans cell histiocytosis (LCH) and hemophagocytic lymphohistiocytosis (HLH). As the leader of the Histiocytosis Service at St. Jude, I serve as the primary attending for all patients diagnosed with histiocytic disorders and manage all outside consults regarding patients with these diagnoses. Additionally, I serve as the Institutional Primary Investigator for several multi-center therapeutic trials for LCH.
Since my initial faculty appointment, I have worked closely with the Clinical Informatics team as a physician advisor on a wide range of projects, and in 2015 I took on the role of Associate Chief Medical Information Officer. My effort as ACMIO is devoted to the refinement the current St. Jude electronic medical record with a focus on improving efficiency and accuracy documentation, improving utilization of the medical record for both patient care and clinical research, and ensuring that the electronic medical record contributes to Patient Safety/Quality Improvement initiatives.
B. Positions and Honors
Positions and Employment
|2008 –||Adjunct Assistant Professor in Pediatrics, University of Tennessee School of Medicine|
|2008 – 2011||Assistant Member, Department of Oncology, St. Jude Children’s Research Hospital|
|2011 – 2015||Staff Physician, Department of Oncology, St. Jude Children’s Research Hospital|
|2015 –||Assistant Member, Department of Oncology, St. Jude Children’s Research Hospital|
|2015 –||Associate Chief Medical Information Officer, St. Jude Children’s Research Hospital|
Other Experience and Professional Memberships
|2005 –||Children’s Oncology Group, Member|
|2008 –||American Society of Pediatric Hematology-Oncology, Member|
|2009 –||Histiocyte Society, Member, Education Committee|
|North American Consortium for Histiocytosis, Member, Executive Committee, Clinical Trials Committee
Cerner Pediatric Leadership Council
National Comprehensive Cancer Network, EHR Advisory Group
|1992 – 1993||Howard Hughes Undergraduate Research Fellowship, Haverford College|
|1993 – 2002||Robert W. Woodruff Fellowship in Medicine, Emory University|
|2011||Resident Teaching Award, St. Jude Children’s Research Hospital|
|2012||Resident Teaching Award, St. Jude Children’s Research Hospital|
|2013||Resident Teaching Award, St. Jude Children’s Research Hospital|
|2014||St. Jude Clinical Care Improvement Award, St. Jude Children’s Research Hospital|
|2014||Resident Teaching Award, St. Jude Children’s Research Hospital|
|2015||St. Jude Outstanding Physician Award, St. Jude Children’s Research Hospital|
C. Contribution to Science
- My primary clinical and academic focus is the biology and treatment of histiocytic disorders, in particular Langerhans cell histiocytosis (LCH). In 2014, I published the St. Jude experience in using clofarabine for the treatment of LCH. This experience contributed to the development of a phase II multi-institutional study of the use of clofarabine in patients with recurrent or refractory LCH. The study has been activated through the North American Consortium for Histiocytosis (NACHO).
Though my involvement with the Histiocyte Society, I have worked for many years on the development of the LCH-IV international collaborative trial for the treatment protocol for newly diagnosed and recurrent LCH. This protocol, on which I serve as the associate national coordinator in United States, opened in the United States in 2015 and is now accruing patients. Though the NACHO consortium and through other collaborative studies, I have been working to develop a better understanding of the pathophysiology and the molecular basis of LCH and Hemophagocytic Lymphohistiocytosis (HLH). The aim of this work is to identify new targeted therapies for these diseases, which can be developed into clinical trials through the NACHO consortium.
- Abraham A, Alsultan A, Jeng M, Rodriguez-Galindo C, Campbell PK. Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis. Pediatr Blood Cancer. 2013 Jun;60(6):E19-22. PubMed PMID: 23255383.
- Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, Sylvester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe J, Ganzel C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block J, Héritier S, Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F, Taylor BS, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA, Abdel-Wahab O. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discov. 2016 Feb;6(2):154-65. PubMed PMID: 26566875; PubMed Central PMCID: PMC4744547.
- McClain KL, Picarsic J, Chakraborty R, Zinn D, Lin H, Abhyankar H, Scull B, Shih A, Lim KPH, Eckstein O, Lubega J, Peters TL, Olea W, Burke T, Ahmed N, Hicks MJ, Tran B, Jones J, Dauser R, Jeng M, Baiocchi R, Schiff D, Goldman S, Heym KM, Wilson H, Carcamo B, Kumar A, Rodriguez-Galindo C, Whipple NS, Campbell P, Murdoch G, Kofler J, Heales S, Malone M, Woltjer R, Quinn JF, Orchard P, Kruer MC, Jaffe R, Manz MG, Lira SA, Parsons DW, Merad M, Man TK, Allen CE. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer 2018;124(12):2607-2620. PubMed PMID: 29624648.
- As an attending physician in the Leukemia/Lymphoma division at St. Jude, I am involved in multiple ongoing prospective and retrospective studies involving our patients. The focus of most of these studies is the prevention and management of complications related to treatment of our patients.
- Rubnitz JE, Campbell P, Zhou Y, Sandlund JT, Jeha S, Ribeiro RC, Inaba H, Bhojwani D, Relling MV, Howard SC, Campana D, Pui CH. Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. Cancer. 2013 Jun 1;119(11):2061-6. PubMed PMID: 23456849; PubMed Central PMCID: PMC3862024.
- Fernandez CA, Stewart E, Panetta JC, Wilkinson MR, Morrison AR, Finkelman FD, Sandlund JT, Pui CH, Jeha S, Relling MV, Campbell PK. Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemother Pharmacol. 2014 Jun;73(6):1307-13. PubMed PMID: 24771103; PubMed Central PMCID: PMC4137479.
- Kaste SC, Pei D, Cheng C, Neel MD, Bowman WP, Ribeiro RC, Metzger ML, Bhojwani D, Inaba H, Campbell P, Rubnitz JE, Jeha S, Sandlund JT, Downing JR, Relling MV, Pui CH, Howard SC. Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids. J Clin Oncol. 2015 Feb 20;33(6):610-5. PubMed PMID: 25605853; PubMed Central PMCID: PMC4322260.
- Nguyen R, Jeha S, Zhou Y, Cao X, Cheng C, Bhojwani D, Campbell P, Howard SC, Rubnitz J, Ribeiro RC, Sandlund JT, Gruber T, Inaba H, Pui CH, Metzger ML. The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia. Pediatr Blood Cancer. 2016 Sep;63(9):1546-51. PubMed PMID: 27187265; PubMed Central PMCID: PMC5131872.
- Quinn M, Fannin JT, Sciasci J, Bragg A, Campbell PK, Carias D, Crews KR, Gregornik D, Jeha S, Maron G, Pauley JL, Swanson H, Wolf J, Greene W. Pentamidine for prophylaxis against Pneumocystis jirovecii pneumonia in pediatric oncology patients receiving immunosuppressive chemotherapy. Antimicrob Agents Chemother, 2018 Jun; AAC00173-18R1. PMID: 29866879.
D. Additional Information: Research Support and/or Scholastic Performance
Ongoing Research Support
318937, St. Baldrick’s Foundation
Carlos Rodriguez-Galindo (PI)
Consortium for Clinical and Translational Research in LCH
Role: Investigator, Institutional PI
Completed Research Support
T32 CA070089, NCI NRSA Institutional Training Grant
Kastan, Michael B (PI)
Investigation of an ABCG2-positive cancer stem cell population in neuroblastoma.